NEW YORK – With $16 million in recently closed Series B funding, Israeli digital microscopy firm Scopio Labs is expanding its commercial operations including a planned US Food and Drug Administration submission for automated hematology diagnostics.
Last month, Scopio received the CE mark for its automated peripheral blood smear system, called X100 Full-Field PBS. The company is currently finishing a multicenter study of the system at sites inside and outside the US that it plans to use as part of an FDA 510(k) submission.